InspireMD Q2 revenue flat at $1.77M; net loss $14.3M on recall charges

InspireMD, Inc.

2026-Q2 EPS reported -$0.33 revenue$5,169,000

Q2 2026 revenue $1.771M, down 0.4% YoY; international up 21% to $2.122M, U.S. negative due to $734K recall credits.
Net loss $14.324M ($0.17/share) vs $13.151M loss ($0.26/share) in Q2 2025; gross loss $774K incl. $612K inventory impairment.
Cash and marketable securities $30.4M at June 30, 2026, down from $54.2M at Dec 31, 2025.
Cost savings actions expected to generate ~$9M annual savings; FDA submissions for CGuard Prime 80 cm and original platform expected later this year.
CGUARDIANS II 30-day outcomes: 100% device success, no deaths/strokes/MI; CGUARDIANS III enrollment started.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.